Atopic dermatitis


AD is the most common dermatosis affecting children: 65% of the patients are less than a year old and 85% are below 5 years. The prevalence of this pathology is constantly on the rise and currently affects 10 to 25% of the population. This increase is related to the lifestyle in industrialized countries, where 20% of the children suffer from this dermatosis.

Clinical signs of atopic dermatitis

The symptoms of AD mainly appear on the skin. Pruritus, an intense itching resulting from xerosis (skin dryness) and histamine release, is the main symptom of this pathology [Ref: MAST-0001; BLOO-0008]. Following this itching, excoriations appear on the skin and form lichenification patches (skin thickening). These skin lesions are accompanied by the formation of oozing scabs as well as erythema and papules. Moreover, in contrast with psoriasis, cutaneous keratinocytes in AD patients express few antimicrobial defense molecules (β-defensin) [Ref: NHEK-0035; NHEK-0037]. This explains why this dermatosis often occurs with complications, among which the most common are bacterial or viral superinfections. For example, Staphylococcus aureus, which is often found in skin superinfections5 [Ref: EPIBA-0060], exacerbates skin inflammation by secreting toxins and may cause impetigo.

Atopic dermatitis: physiopathology

The cause of AD is often linked to an epidermal barrier dysfunction, generally due to a mutation in the filaggrin gene. This structural anomaly facilitates skin lesions and leads to increased skin permeability, promoting the entry of antigens. Barrier dysfunction and antigen entry are at the root of the sensitization stage of AD. It is in a second stage, called the effector stage, that the appearance of pathological symptoms is noticed. This stage may be divided into several steps: initiation, activation of dendritic cells, polarization of Th2/Th22 lymphocytes as well as activation of other agents of AD (mast cells, etc.) and finally, an inflammatory loop between the keratinocyte and the infiltrating cells, leading to pathological skin.

Check out Bioalternatives’ updates and experience new testing ideas

  • New assays, models and services
  • Posts and publications
  • Events
  • The legal basis for the processing is consent. Your e-mail address will only be communicated to the following recipients: the departments concerned and authorised by QIMA LIFE SCIENCE. This data is kept for as long as you are registered to the newsletter.

    You can access your data, rectify it, request its deletion or exercise your right to limit the processing of your data, withdraw your consent to the processing of your data at any time, oppose the processing of your data and you have a right to the portability of your data.

    Visit for more information on your rights.
    You can exercise all your rights using the following linkGestion des droits or by writing to If you feel, after contacting us, that your "Informatique et Libertés" rights are not being respected, you can submit a complaint to the CNIL.

  • The information collected on this form is recorded in a file used by QIMA Life Sciences to send you its newsletter.